Pre-And post-Androgen deprivation lipid profiles of men with prostate cancer A multi-center study
Keywords:
Androgen deprivation treatment, Prostate carcinoma, Lipid profileAbstract
Introduction: Dyslipidemia is the primary cause of hospitalization and death in men with advanced prostate cancer. Our goal was to examine how androgen deprivation therapy (ADT) affects lipid profiles in Indian men with locally progressed or metastatic prostate cancer. Methods: this multi center study was conducted in LRH urology department From jan 2020 to jan 2021 Patients with prostate cancer who received ADT and for whom lipid account data from the first two years of ADT treatment was available were split into two groups for retrospective analysis. Members of Group A had bilateral orchidectomy, whereas those in Group B were given a luteinizing hormone-releasing hormone agonist (LHRHa). The information considered are quality standards, prostate-specific antigen (PSA), and lipid profiles. Results: 69 eligible patients were divided evenly between teams A (29) and B (40). After starting ADT, the median blood PSA level dropped significantly in both groups and remained low until 24 months. At six months, there was a statistically insignificant decline in all lipid profile parameters in team A patients except for high-density lipoprotein cholesterol.
Downloads
References
Flaig TW, Glode LM (2008). Management of the side effects of androgen deprivation therapy in men with prostate cancer. Expert OpinPharmaco- the 9:2829–2841
Jeong SJ, Kwak C, Lee SE (2001). The therapeutic effect of maximal androgen blockade in metastatic prostate cancer. Korean J Urol 42:642–649
Keating NL, O'Malley AJ, Smith MR (2006). Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J ClinOncol 24(27):4448–4456
Moorjani S, Dupont A, Labrie F, et al. (1988). Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide. J Clin Endocrinol Metab 66(2):314–322
Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. (2011). EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 59:572–583
Østergren PB, Kistorp C, Fode M, Bennedbaek FN, Faber J, Sønksen J (2019). Metabolic consequences of gonadotropin-releasing hormone agonists vs. orchiectomy: a randomized clinical study. BJU Int 123(4):602–611
Pope A, Abel P (2010). Androgen deprivation therapy for prostate cancer and its complications. Trends Urol Gynaecol Sex Health 15(3):32–37
Prospective Study Collaboration, Lewington S, Whitlock G, Clarke R, et al. (2007) Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370:1829– 1839
Rawla P (2019). Epidemiology of prostate cancer. World J Oncol 10(2):63–89
Ryan CJ, Small EJ (2005) Early versus delayed androgen deprivation for prostate cancer: new fuel for an old debate. J ClinOncol 23:8225–8231
Sağlam HS, Köse O, Kumar S, Budak S, Adsan O (2012) Fasting blood glucose and lipid profile alterations following twelve-month androgen deprivation therapy in men with prostate cancer. Sci World J 2012:696329
Salvador C, Planas J, Agreda F, et al. (2013) Analysis of the lipid profile and atherogenic risk during androgen deprivation therapy in prostate cancer patients. Urol Int 90(1):41–44
Smith JC, Bennett S, Evans LM et al. (2001) The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 86:4261–4267
Sun M, Choueiri TK, Hamnvik OP, et al. (2016) Comparison of gonadotropin-releasing hormone agonists and orchiectomy: effects of androgen-deprivation therapy. JAMA Oncol 2(4):500–507
Thomsen FB, Sandin F, Garmo H, et al. (2017) Gonadotropin-releasing hormone agonists, orchiectomy, and risk of cardiovascular disease: semi-ecologic, nationwide, population-based study. Eur Urol 72(6):920–928
Torimoto K, Samma S, Kobayashi Y, et al. (2011) The effects of androgen deprivation therapy on lipid metabolism and body composition in Japa- nese patients with prostate cancer. Jpn J ClinOncol 41(4):577–581
Published
How to Cite
Issue
Section
Copyright (c) 2023 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
